Loading…
Alto Neuroscience, Inc. is projected to rise to $38.15 by 2027, a +44% move from its current price of $26.48. ANRO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $25.51 | $26.52 | $27.57 | +0.15% |
| Jul 14 | $25.13 | $26.56 | $28.06 | +0.30% |
| Jul 15 | $24.86 | $26.60 | $28.46 | +0.45% |
| Jul 16 | $24.64 | $26.64 | $28.80 | +0.60% |
| Jul 17 | $24.45 | $26.68 | $29.11 | +0.74% |
| Jul 18 | $24.28 | $26.72 | $29.39 | +0.89% |
| Jul 19 | $24.13 | $26.76 | $29.66 | +1.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.13 | $26.76 | $29.66 | +1.04% |
| Week 2 | $23.37 | $27.04 | $31.28 | +2.10% |
| Week 3 | $22.85 | $27.32 | $32.66 | +3.17% |
| Week 4 | $22.46 | $27.60 | $33.93 | +4.24% |
| Week 5 | $22.15 | $27.89 | $35.13 | +5.33% |
| Week 6 | $21.89 | $28.18 | $36.29 | +6.43% |
| Week 7 | $21.67 | $28.48 | $37.41 | +7.54% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
Its product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease.
The company was incorporated in 2019 and is headquartered in Mountain View, California.
Alto Neuroscience, Inc. (ANRO) is currently priced at $27.64 with a market cap of $970M and a rank of 2598. The current price is situated within a broader forecast that shows a neutral near-term view but a bullish long-term trajectory.
The 2026 forecast lists a min of $14.11, an avg of $27.64, and a max of $43.82, underscoring a baseline identical to today’s price in the middle of the range.
Looking further out, the forecast depicts a pronounced upward path, with yearly averages climbing toward higher price levels through 2050 and beyond. The long-horizon outlook shows substantial upside, with the 2040 and 2050 projections featuring notable gains and rising ROIs, though these are estimates and not guarantees.
A major floor 45.5% below — a decisive break under it would weaken the trend.
The nearest floor, 31.1% below — buyers have tended to step in here.
The nearest ceiling, 6.0% above — a clean break opens room to run.
A major ceiling 28.8% above — clearing it would confirm fresh momentum.
Key ANRO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANRO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $26.43 | Buy | $26.45 | Buy |
| MA 10 | $26.34 | Buy | $25.92 | Buy |
| MA 20 | $24.53 | Buy | $24.82 | Buy |
| MA 50 | $23.00 | Buy | $23.43 | Buy |
| MA 100 | $22.57 | Buy | $21.79 | Buy |
| MA 200 | $17.88 | Buy | $18.32 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.99 | Neutral |
| Stoch RSI (14) | 15.74 | Buy |
| CCI (20) | 67.68 | Neutral |
| Williams %R (14) | -30.93 | Info |
| MACD (12,26,9) | 0.18 | Buy |
| ROC (12) | 8.35 | Buy |
| Bollinger %B (20,2) | 0.72 | Neutral |
| Stochastic %K (14) | 69.07 | Neutral |
| TRIX (15) | 0.74 | Buy |
| Awesome (5,34) | 3.78 | Buy |
| Ultimate (7,14,28) | 56.02 | Neutral |
| Momentum (10) | 1.18 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 26.86 | Sell |
| ADX (14) | 21.12 | Buy |
| ATR (14) | 0.93 | Info |
The 30-day technical picture is bullish, supporting a constructive near-term view.
RSI14 sits at 60, and the stock is trading above the SMA50 ($22.96) and the SMA200 ($17.77), suggesting positive momentum.
The 30-day range runs from $21.37 to $35.76, with support at $18.24 and resistance at $28.07. The stock also exhibits high volatility, with annualized volatility around 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.11 | $26.48 | $41.85 | 0% | Neutral | |
| $29.16 | $38.15 | $53.45 | +44% | Bullish | |
| $43.84 | $59.80 | $88.05 | +126% | Bullish | |
| $52.29 | $73.87 | $113.05 | +179% | Bullish | |
| $51.92 | $75.67 | $119.58 | +186% | Bullish | |
| $57.43 | $86.15 | $139.99 | +225% | Bullish | |
| $61.68 | $95.07 | $158.36 | +259% | Bullish | |
| $73.94 | $116.94 | $199.19 | +342% | Bullish | |
| $95.36 | $154.58 | $268.74 | +484% | Bullish | |
| $103.27 | $171.43 | $303.71 | +547% | Bullish | |
| $160.24 | $297.17 | $569.41 | +10.2x | Bullish | |
| $262.37 | $583.04 | $1,249.53 | +21.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.11 | $26.48 | $32.84 | +0.00% |
| August 2026 | $24.77 | $29.58 | $36.50 | +11.69% |
| September 2026 | $25.14 | $30.32 | $38.00 | +2.50% |
| October 2026 | $24.48 | $29.78 | $37.82 | -1.77% |
| November 2026 | $25.18 | $30.87 | $39.63 | +3.65% |
| December 2026 | $26.15 | $32.28 | $41.85 | +4.57% |
Click any year to see its month-by-month ANRO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ANRO price prediction for 2026 points to an average of $26.48 (low $14.11, high $41.85) — a potential gain of 0% on today's $26.48. A consolidation phase looks the most probable path here.
In 2027, ANRO is projected to trade between $29.16 and $53.45, averaging $38.15 — a potential gain of +44% from today's $26.48. That is up +44% on the projected 2026 average. Momentum favours further upside here.
Alto Neuroscience, Inc.'s 2028 outlook centres on $59.80, within a $43.84 to $88.05 range. That is up +57% on the projected 2027 average. That marks a +126% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ANRO could reach as high as $113.05, with a base case around $73.87 and support toward $52.29 — roughly +179% from $26.48. Momentum favours further upside here.
Expect ANRO to range from $51.92 to $119.58 through 2030. The $75.67 average target implies a +186% move from current prices. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ANRO price prediction for 2031 points to an average of $86.15 (low $57.43, high $139.99) — a potential gain of +225% on today's $26.48. Momentum favours further upside here.
In 2032, ANRO is projected to trade between $61.68 and $158.36, averaging $95.07 — a potential gain of +259% from today's $26.48. That is up +10% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Alto Neuroscience, Inc.'s 2033 outlook centres on $116.94, within a $73.94 to $199.19 range. That is up +23% on the projected 2032 average. That marks a +342% change versus current levels. Momentum favours further upside here.
By 2034, ANRO could reach as high as $268.74, with a base case around $154.58 and support toward $95.36 — roughly +484% from $26.48. Buyers look set to stay in control over this stretch.
Expect ANRO to range from $103.27 to $303.71 through 2035. The $171.43 average target implies a +547% move from current prices. That is up +11% on the projected 2034 average. Momentum favours further upside here.
The ANRO price prediction for 2040 points to an average of $297.17 (low $160.24, high $569.41) — a potential gain of +10.2x on today's $26.48. Buyers look set to stay in control over this stretch.
In 2050, ANRO is projected to trade between $262.37 and $1,249.53, averaging $583.04 — a potential gain of +21.0x from today's $26.48. That is up +96% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ANRO today (≈ 37.76435 ANRO) could be worth
$22,018.11
+$21,018.11 (+2102%) by 2050 · US Dollar
Based on the average projected ANRO price of $583.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANROwould be worth at today's price.
$1,000 invested in ANRO on Jul 10, 2025 (≈ 387.596911 ANRO) would be worth
$10,263.57
+$9,263.57 (+926.4%) today · 10.26× · US Dollar
Based on a ANRO entry price of $2.58 vs. today's $26.48.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.78 | $1,068.6 | +6.9% |
| 1 month ago | $19.68 | $1,345.53 | +34.6% |
| 3 months ago | $22.78 | $1,162.42 | +16.2% |
| 6 months ago | $16.94 | $1,563.16 | +56.3% |
| 1 year ago | $2.58 | $10,263.57 | +926.4% |
| All time (2.4y) ago | $20.7 | $1,279.23 | +27.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANRO forecast.
Our base-case forecast reaches $53.00 around 2028.
Implied market cap at $53.00: $1.86B
The multi-year forecast shows a sustained bullish trajectory across the horizon. In 2027 the avg is $40.27 with a max of $56.46 and a ROI of 45.7%, followed by 2028 avg $62.73 (max $92.44, ROI 127) and 2029 avg $76.35 (max $116.91, ROI 176.2).
In 2030 the avg rises to $77.46 with a max of $122.49 and a ROI of 180.3%, and the sentiment remains BULLISH. By 2031 the avg is $88.61 (max $144.07, ROI 220.6%), by 2032 $97.78 (max $162.97, ROI 253.8%), and by 2033 $121.12 (max $206.45, ROI 338.2%). The upward path continues to 2034 (avg $159.70, max $277.82, ROI 477.8%) and 2035 (avg $174.70, max $309.73, ROI 532.1%).
Longer-range projections show substantial upside: 2040 has an avg of $305.12 (max $585.07, ROI 1003.9%), and 2050 has an avg of $586.91 (max $1,258.88, ROI 2023.4%), with sentiment remaining BULLISH.
These figures illustrate a strong long-term growth path, but they are estimates and not guarantees. Investors should consider the inherent uncertainty in forward-looking forecasts.
Tap a question to reveal the answer.
The 2030 forecast lists min $53.11, avg $77.46, max $122.49 with ROI 180.3% and sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with rising averages and ROIs including 2027 avg $40.27 (ROI 45.7%), 2028 avg $62.73 (ROI 127%), 2029 avg $76.35 (ROI 176.2%), and 2030 avg $77.46 (ROI 180.3%), followed by higher levels through 2050; these are estimates, not guarantees.
Yes, the 2030 max is $122.49 with an avg of $77.46 and ROI of 180.3%, indicating potential upside under the forecast assumptions.
Current price is $27.64 and market cap is $970M.
Sentiment is BULLISH. RSI14 is 60. SMA50 is $22.96 and SMA200 is $17.77. The 30-day range is $21.37 to $35.76 with support at $18.24 and resistance at $28.07.
Alto Neuroscience, Inc. Community Discussion
0Share your Alto Neuroscience, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.